Ginkgo Bioworks Holdings annual capital expenditures (capex)
2019
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings Capital Expenditures (CapEx) Growth & History (DNA)
Ginkgo Bioworks Holdings's capital expenditures (capex) was $7.7M for fiscal 2025.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.7M | −$54.9M | −87.74% |
| 2024 | 2024-12-31 | $62.5M | $21.7M | +53.28% |
| 2023 | 2023-12-31 | $40.8M | −$11.5M | −21.94% |
| 2022 | 2022-12-31 | $52.3M | −$4.3M | −7.52% |
| 2021 | 2021-12-31 | $56.5M | −$1.3M | −2.25% |
| 2020 | 2020-12-31 | $57.8M | $35.6M | +160.23% |
| 2019 | 2019-12-31 | $22.2M | — | — |
Ginkgo Bioworks Holdings quarterly capital expenditures (capex)
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.6M | $2.6M | +6792.11% |
| Q1 2026 | 2026-03-31 | $1.9M | −$5.7M | −74.64% |
| Q4 2025 | 2025-12-31 | $5,000 | −$13.7M | −99.96% |
| Q3 2025 | 2025-09-30 | $0 | −$15.1M | — |
| Q2 2025 | 2025-06-30 | $38,000 | −$27.0M | −99.86% |
| Q1 2025 | 2025-03-31 | $7.6M | $912,000 | +13.59% |
| Q4 2024 | 2024-12-31 | $13.7M | $10.3M | +297.85% |
| Q3 2024 | 2024-09-30 | $15.1M | $10.7M | +244.42% |
| Q2 2024 | 2024-06-30 | $27.0M | $13.5M | +99.75% |
| Q1 2024 | 2024-03-31 | $6.7M | −$12.7M | −65.49% |
| Q4 2023 | 2023-12-31 | $3.4M | −$22.2M | −86.56% |
| Q3 2023 | 2023-09-30 | $4.4M | −$9.1M | −67.48% |
| Q2 2023 | 2023-06-30 | $13.5M | $4.0M | +41.37% |
| Q1 2023 | 2023-03-31 | $19.4M | $15.9M | +443.04% |
| Q4 2022 | 2022-12-31 | $25.6M | $20.5M | +401.47% |
| Q3 2022 | 2022-09-30 | $13.5M | $8.0M | +147.76% |
| Q2 2022 | 2022-06-30 | $9.6M | −$14.5M | −60.17% |
| Q1 2022 | 2022-03-31 | $3.6M | −$18.4M | −83.68% |
| Q4 2021 | 2021-12-31 | $5.1M | — | — |
| Q3 2021 | 2021-09-30 | $5.4M | — | — |
| Q2 2021 | 2021-06-30 | $24.0M | — | — |
| Q1 2021 | 2021-03-31 | $21.9M | — | — |
Ginkgo Bioworks Holdings capital expenditures (capex) trends
Over the last five fiscal years, Ginkgo Bioworks Holdings's capital expenditures (capex) decreased from $57.8M to $7.7M, a change of −$50.2M. The latest reported quarter, Q2 2026, shows $2.6M.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...